Janux Therapeutics DEF 14A: Executive Compensation Details
Ticker: JANX · Form: DEF 14A · Filed: Apr 25, 2025 · CIK: 1817713
| Field | Detail |
|---|---|
| Company | Janux Therapeutics, Inc. (JANX) |
| Form Type | DEF 14A |
| Filed Date | Apr 25, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, equity-awards, sec-filing, DEF-14A
TL;DR
Janux Therapeutics DEF 14A out: Executive pay & equity awards for 2023-2024 detailed. Focus on fair value of grants.
AI Summary
Janux Therapeutics, Inc. filed a DEF 14A on April 25, 2025, detailing executive compensation and equity awards for the fiscal years ending December 31, 2023, and 2024. The filing includes information on the fair value of equity awards granted, outstanding awards, and changes in their fair value for both "Peo" (likely Named Executive Officers) and "NonPeoNeo" (likely Non-Employee Directors) members. Specific dollar amounts for these awards are not detailed in this excerpt but are central to the compensation structure.
Why It Matters
This filing provides transparency into how Janux Therapeutics compensates its top executives and board members, which can influence investor decisions and perceptions of company governance.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine disclosures about executive compensation, but the specifics of equity awards can signal future dilution or management incentives, impacting stock value.
Key Players & Entities
- Janux Therapeutics, Inc. (company) — Filer of the DEF 14A
- 0000950170-25-058806 (filing_id) — Accession Number for the filing
- 20250425 (date) — Filing date
- 1231 (date) — Fiscal year end
- 2023-01-01 (date) — Start of fiscal year for compensation data
- 2023-12-31 (date) — End of fiscal year for compensation data
- 2024-01-01 (date) — Start of fiscal year for compensation data
- 2024-12-31 (date) — End of fiscal year for compensation data
FAQ
What is the primary purpose of this DEF 14A filing by Janux Therapeutics?
The primary purpose is to disclose information regarding executive compensation, including details on equity awards granted and their fair values for the fiscal years ending December 31, 2023, and December 31, 2024.
Which fiscal years are covered by the compensation data in this filing?
The filing covers compensation data for the fiscal years ending December 31, 2023, and December 31, 2024.
What types of equity awards are detailed in the filing?
The filing details equity awards granted, outstanding equity awards, and changes in the fair value of equity awards for both "Peo" (likely Named Executive Officers) and "NonPeoNeo" (likely Non-Employee Directors) members.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted to the SEC on April 25, 2025.
What is the standard industrial classification for Janux Therapeutics?
The standard industrial classification for Janux Therapeutics is Pharmaceutical Preparations [2834].
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 25, 2025 regarding Janux Therapeutics, Inc. (JANX).